Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

Abstract

To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PBC) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC). The addition of dulanermin to PC and PCB did not improve outcomes in unselected patients with previously untreated advanced or recurrent NSCLC.

Keywords

• Chemotherapy
• dulanermin
• carboplatin
• bevacizumab
• paclitaxel
• NSCLC